ABSTRACT
Pertussis is one of the leading causes of death that can be prevented by vaccination. More than 600,000 deaths from pertussis occur annually, with a disproportionate number appearing in unvaccinated infants. Pertussis is particularly troublesome because it does not necessarily present itself in its commonly known classical stages. Therefore, in very young and non-immunized children, the disease may have a fulminant process characterized by severe leukocytosis, neurologic involvement and serious cardiopulmonary failure that can be accompanied by pulmonary hypertension, persistent hypoxia and death. This article describes two infants with fulminant pertussis; they were admitted for acute respiratory failure and severe leukocytosis and ultimately died from multi-organ failure.
Subject(s)
Bordetella pertussis/immunology , Pertussis Vaccine/pharmacology , Vaccination/methods , Whooping Cough/therapy , Acute Disease , Fatal Outcome , Female , Humans , Infant , MaleABSTRACT
BACKGROUND: The aim of this study was to investigate the efficacy and safety of colistin therapy in pediatric patients with severe nosocomial infections in pediatric intensive care unit. METHODS: The medical records of patients treated with colistin at a 200-bed university children hospital were reviewed. RESULT: Thirty-one patients (male/female = 22/9; median age, 3 years; range, 3 months-17 years) received forty-one courses of colistin. The average dose of colistin was 4.9 ± 0.5 mg/kg/day and average treatment duration was 19.8 ± 10.3 days. Three patients who received concomitant nephrotoxic agent with colistin developed nephrotoxicity. Colistin treatment was well tolerated in other patients, and neurotoxicity was not seen in any patient. Favourable outcome was achieved in 28 (68.3%) episodes. Twelve patients died during the colistin therapy. Six of these patients died because of primary underlying disease. The infection-related mortality rate was found 14.6% in this study. CONCLUSION: In our study, colistin therapy was found to be acceptable treatment option for the severe pediatric nosocomial infections caused by multi-drug resistant bacteria. However, the use of concomitant nephrotoxic drugs with colistin must be avoided and renal function test should be closely monitored.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Colistin/therapeutic use , Cross Infection/drug therapy , Acute Kidney Injury/chemically induced , Acute Kidney Injury/epidemiology , Adolescent , Anti-Bacterial Agents/adverse effects , Child , Child, Preschool , Colistin/adverse effects , Female , Hospitals, University , Humans , Infant , Intensive Care Units, Pediatric , Male , Treatment OutcomeABSTRACT
Nosocomial infections caused by multidrug-resistant (MDR) microorganisms are a common problem around the world, especially in Intensive Care Units. The aim of this study was to investigate the efficacy and safety of colistin therapy in paediatric patients with severe nosocomial infections caused by MDR Gram-negative bacteria. There were 87 episodes in 79 paediatric Intensive Care Unit patients in five different hospitals; each patient was treated intravenously with colistin and evaluated. Of the 79 patients, 54.4% were male and the median age was 30 months. The most commonly isolated microorganism was Acinetobacter baumannii, the most common isolation site was tracheal aspirate fluid and the most common type of infection was ventilator-associated pneumonia. The mean colistin dose in patients without renal failure was 5.4 ± 0.6 mg/kg/day, the mean therapy duration was 17.2 ± 8.4 days and the favourable outcome rate was 83.9%. Serious side effects were seen in four patient episodes (4.6%) during therapy; two patients suffered renal failure and the others had convulsive seizures. Other patients tolerated the drug well. The infection-related mortality rate was 11.5% and the probability of death within the first 9 days of treatment was 10 times higher than after the first 9 days. In conclusion, this study suggests that colistin is effective in the treatment of severe nosocomial infections caused by MDR Gram-negative bacteria and is generally well tolerated by patients, even after relatively long-term use.
Subject(s)
Acinetobacter Infections/drug therapy , Colistin/therapeutic use , Intensive Care Units, Pediatric , Pseudomonas Infections/drug therapy , Acinetobacter Infections/microbiology , Acinetobacter baumannii/isolation & purification , Acinetobacter baumannii/pathogenicity , Adolescent , Child , Child, Preschool , Colistin/administration & dosage , Colistin/adverse effects , Cross Infection/drug therapy , Cross Infection/microbiology , Drug Administration Schedule , Drug Evaluation/methods , Drug Resistance, Multiple, Bacterial , Female , Humans , Infant , Male , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/isolation & purification , Pseudomonas aeruginosa/pathogenicity , Renal Insufficiency/chemically induced , Retrospective Studies , Seizures/chemically induced , Time Factors , Treatment OutcomeABSTRACT
Reexpansion pulmonary edema is an uncommon complication following rapid reexpansion of the lungs. The risk increases with a prolonged duration of pulmonary collapse, the amount of drained liquid or air, and with decreased time of draining. Treatment is supportive. In general, the prognosis is favorable. A nine-year-old boy was presented with fever, cough, and respiratory distress. Pneumonia and left-sided pleural empyema were determined and a chest tube was emplaced. Clinical deterioration occurred in just a few minutes following chest tube insertion. His chest radiography revealed a pulmonary edema in the left lung. Despite mechanical ventilation, antibiotics, and diuretic treatment, no significant improvement occurred. Acute respiratory distress syndrome and multiple organ dysfunctions developed in the follow-up. The patient died on day 5 of hospitalization. In this report, a complicated reexpansion pulmonary edema with a lathal outcome in a 9-year-old child is presented.
